© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Latest Conference Articles
Recognizing Allergic Contact Dermatitis in Children: Expert Pearls at AAD 2025
March 10th 2025
JiaDe Yu, MD, shares key takeaways from his presentation on pediatric allergic contact dermatitis.
Brian S. Kim, MD: Why Primary Care Clinicians Should Prescribe New Treatments for Atopic Dermatitis
March 10th 2025
Brian S. Kim, MD, a worldwide leader in research into itch and other skin conditions, says the safety profile and ease of use of new treatments for AD mean primary care clinicians should definitely consider prescribing them.
Zabalafin Hydrogel Shows Efficacy in Atopic Dermatitis, Including Cases with Bacterial Infection
March 10th 2025
Data on zabalafin hydrogel topical therapy may offer a single, comprehensive approach to manage AD across multiple disease stages.
The Link Between Itch and Aging, with Daniel Butler, MD
March 10th 2025
Daniel Butler, MD, discusses a more complex definition of immunosenescence, and the interplay between aging and itch-related conditions.
The Complexities of Treating Rosacea, with Benjamin Ungar, MD
March 10th 2025
Benjamin Ungar, MD, explains the phenotypic and molecular manifestations of Rosacea, and the work still needed to develop targeted treatments.
Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast
March 9th 2025
“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.
Daniel Butler, MD: Pearls for Primary Care When Treating and Referring Older Adults for Chronic Itch
March 9th 2025
Butler addresses how primary care can help manage the burdens of itch in their older patients and offers pearls for consulting and referring to dermatology.
Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings
March 9th 2025
Approximately one-third of participants treated with rocatinlimab achieved EASI-75 at 24 weeks, more than 2 times the proportion in the placebo group, among other robust findings.
Atopic Dermatitis Breakthrough: Linda Stein Gold, MD, on Tapinarof's Treatment-Free Benefits
March 9th 2025
AAD 2025. Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial.
Benjmain Ungar, MD: Addressing the Immunological Causes of Seborrheic Dermatitis
March 9th 2025
Benjamin Ungar, MD, discusses his presentation at AAD 2025 covering advances and updates about rosacea and seborrheic dermatitis.